Pediatric Cancer Clinical Trial
Official title:
A Pilot Study of Assessing and Improving Cognition and Real-World Behavior in Pediatric Cancer Survivors
This pilot study will evaluate the cognitive and behavioral outcomes of using a novel, adaptive attention training in pediatric cancer survivors.
Status | Recruiting |
Enrollment | 70 |
Est. completion date | May 31, 2025 |
Est. primary completion date | May 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 7 Years to 17 Years |
Eligibility | Inclusion Criteria: 1. Age 7-17 at the time of enrollment. 2. Able to understand study procedures and to comply with them for the entire length of the study. 3. Ability of individual and legal guardian/representative to understand a written informed consent document, and the willingness to sign it. 4. Normal or corrected-normal vision and hearing. 5. English language fluency (minor participant and parent/guardian). 6. Received radiation therapy to the brain or neck between age 7-17. 7. Patients not on current cancer-related treatment (except supportive care) or those on other current treatments that would not hinder study participation. Patients currently on cancer-related treatments will be discussed with the study team (co-PI Mueller). Exclusion Criteria: 1. Contraindication to any study-related procedure or assessment. 2. Motor/perceptual difficulties that prevent computer or tablet use. 3. Current cancer-related treatments that would impact the ability to participate in the study (e.g., current inpatient chemotherapy or intrathecal chemotherapy). Patients on other current treatments will be discussed with the study team (co-PI, Dr. Mueller) |
Country | Name | City | State |
---|---|---|---|
United States | Univeristy of California, San Francisco | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
University of California, San Francisco |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in sub-test scores on the Adaptive Cognitive Evaluation (ACE) neuropsychological battery | The ACE is a mobile cognitive assessment tool, which includes a battery of cognitive control tests for rapid tests of cognition. The sub-tests (or 'modules') in ACE are adapted from standardized tasks to rapidly assess various aspects of cognition, including attention, memory, and multitasking. | Up to 8 weeks | |
Other | Change in mean performance on a computerized Math Fluency Test | To assess math fluency, participants solve simple math problems (e.g., addition, subtraction, multiplication) over a 3-minute period. Performance is measured as the number of correct responses. | Up to 8 weeks | |
Other | Change in mean performance on a computerized Reading Fluency Test | To assess reading fluency, participants indicate whether sentences are 'True' or 'False' over a 3-minute period. Performance is measured as the number of correct responses. | Up to 8 weeks | |
Other | Change in mean scores on the Mindful Attention Awareness Scale (MAAS) over time | The MAAS is a 15-item scale designed to assess a core characteristic of mindfulness by asking participants to respond to statements about everyday experiences on a scale from 1="Almost always" to 6="Almost never". The total score is obtained by averaging the scores of the 15 items, to generate a total score for from 1-6. Greater scores are indicative of a greater level of mindfulness. | Up to 8 weeks | |
Other | Change in mean scores on the Warwick-Edinburgh Mental Well-Being Scale (WEMWBS) over time | The 14-item scale WEMWBS addresses mental well-being by asking participants to respond to individual items on a scale from 1="None of the time" to 5="All of the time". The total score is obtained by summing the scores for each of the 14 items, to generate a total score ranging from 14-70. Lower scores are indicative of a lower overall well-being. | Up to 8 weeks | |
Other | Change in mean scores on a modified Insomnia Severity Index (ISI) Scale over time | The modified ISI consists of the first three of seven items in the full ISI scale. These three questions ask participants about the the severity of their insomnia symptoms on a scale from 0="None" to 4="Very". The total score is obtained by summing the scores for each of the three items, to generate a total score from 0-12. Higher scores are indicative of more insomnia problems. | Up to 8 weeks | |
Other | Change in mean scores on the Child Self-Control Rating Scale (parent rating) over time | The Child Self-Control Rating Scale consists of 33 items that assess children's self control. Parents respond to individual items on a 7-point scale. The total score is obtained by summing the scores for each of the 33 items, with a higher score reflecting greater lack of child self-control. | Up to 8 weeks | |
Other | Change in mean performance on a Delay Discounting Task over time | The Delay Discounting task is an untimed task, where participants choose between smaller, more immediate rewards and larger, more delayed rewards. Performance will be quantified by comparing choices between smaller/immediate rewards and larger/delayed rewards as the rate of delay discounting (the hyperbolic discounting index). | Up to 8 weeks | |
Primary | Proportion of participants who complete study | The proportion of participants who completed the study procedures will be reported by study cohort. | Up to 8 weeks | |
Secondary | Change in mean performance on a Continuous Performance Task (CPT) over time | The CPT is a 23-minute task, where participants are instructed to respond to target stimuli (squares at the top of the screen) and withhold responses to non-target stimuli (squares at the bottom of the screen). Performance will be quantified as: (1) mean reaction times, (2) standard deviation of reaction times (RTV), and (3) d-prime (comparing correct target detections or 'hits' to incorrect non-target detections or 'false alarms'). | Up to 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Not yet recruiting |
NCT06335745 -
PediCARE Health Equity Intervention in High-Risk Neuroblastoma
|
N/A | |
Withdrawn |
NCT04719416 -
Relaxation Therapy in Pediatric Oncology
|
N/A | |
Completed |
NCT01645436 -
Physical Activity in Pediatric Cancer (PAPEC)
|
N/A | |
Completed |
NCT04409301 -
Distress in the Pediatric Oncology Setting: Intervention Versus Natural Adaptation
|
N/A | |
Completed |
NCT04914702 -
Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
|
||
Recruiting |
NCT05425043 -
Granulocyte Transfusions After Umbilical Cord Blood Transplant
|
N/A | |
Recruiting |
NCT05071859 -
Genetic Overlap Between Anomalies and Cancer in Kids in the Children's Oncology Group: The COG GOBACK Study
|
||
Recruiting |
NCT03241251 -
Screening for Psychosocial Risk in Flemish Families of a Child With Cancer
|
||
Recruiting |
NCT05384288 -
Response to Influenza Vaccination in Pediatric Oncology Patients
|
||
Completed |
NCT04586491 -
The Effect of Oral Care Protocol on Prevention of Oral Mucositis in Pediatric Cancer Patients
|
N/A | |
Recruiting |
NCT05569512 -
Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT05294380 -
Determination of Sarcopenia Risk and Related Factors in Pediatric Oncological Patients
|
||
Completed |
NCT02675166 -
Getting Long-term Management of Adult Children Cured of Childhood Cancer in Rhône-Alpes
|
||
Completed |
NCT02665819 -
Long Term Support for Pediatric Cancer Adult Survivors in Rhône-Alpes : Evaluation of Women Fertility.
|
N/A | |
Not yet recruiting |
NCT05454163 -
Post-radiotherapy Rhinosinusitis in Children
|
||
Terminated |
NCT02536183 -
A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT01828502 -
Cotinine Feedback as an Intervention to Change Parental/Caregiver Smoking Behavior Around Children With Cancer
|
Phase 2 | |
Completed |
NCT02032121 -
Vascular Endothelial Inflammation and Dysfunction in Pediatric Long-term Cancer Survivors
|
N/A | |
Completed |
NCT03964259 -
Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia
|
Phase 1 |